Astellas reports positive data from overactive bladder drug trial

Astellas has announced results from a phase IIIb trial demonstrating the benefits offered by a new add-on therapy for the treatment of incontinent overactive bladder.

Data from the BESIDE clinical study demonstrated that solifenacin, when used in combination with mirabegron as an add-on therapy, was superior to solifenacin monotherapy in incontinent overactive bladder patients.

The mean number of daily incontinence episodes was reduced by 1.80 episodes in patients given solifenacin with mirabegron, compared to a reduction of 1.53 episodes seen with the monotherapy.

In addition, the add-on treatment was shown to be superior in terms of daily reduction in micturitions and urine volume voided.

Professor Marcus Drake of the University of Bristol and Bristol Urological Institute said: "Such a combined use may help practitioners address the continued unmet need for additional treatment options that can help people living with this debilitating condition."

The company also announced this week that it will be attending the American Urological Association's annual meeting, where it will be presenting new data on its cancer drug enzalutamide.